Atrial fibrillation articles within Nature Medicine

Featured

• Article
  17 May 2024 | Open Access

  Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial

  In a randomized trial testing two types of catheter ablation treatments for persistent atrial fibrillation, a large-tip, dual pulsed field and radiofrequency catheter with a large footprint was non-inferior to a conventional radiofrequency catheter.

  • Elad Anter
  • , Moussa Mansour
  •  & Vivek Y. Reddy

• Article
  13 December 2023 | Open Access

  Inhibition of the K_Ca2 potassium channel in atrial fibrillation: a randomized phase 2 trial

  In a phase 2 clinical trial, an inhibitor of the K_Ca2 potassium channel, which conducts a repolarizing current in the heart, met the primary endpoint of promoting cardioversion from atrial fibrillation to sinus rhythm within 90 minutes of drug administration.

  • Anders G. Holst
  • , János Tomcsányi
  •  & Paul Dorian

• Article | 28 August 2022

  Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial

  In a randomized clinical trial enrolling individuals at risk of stroke, the detection rate of atrial fibrillation that required medication within 6 months was more than doubled in those participants who screened themselves for an irregular pulse using their own smartphone, as compared to usual care.

  • Konstantinos D. Rizas
  • , Luisa Freyer
  •  & Axel Bauer

• Letter | 09 March 2020

  Deep learning models for electrocardiograms are susceptible to adversarial attack

  The development of an algorithm that can imperceptibly manipulate electrocardiographic data to fool a deep learning model for diagnosing cardiac arrhythmia highlights the potential vulnerability of artificial intelligence-enabled diagnosis to adversarial attacks.

  • Xintian Han
  • , Yuxuan Hu
  •  & Rajesh Ranganath

• Letter | 21 March 2010

  Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation

  Although the precipitating mechanisms of atrial fibrillation are not fully understood, atrial fibrosis is thought to set the stage for arrhythmia. Volker Rudolph et al. now show that the enzyme myeloperoxidase, released by inflammatory cells, is a key inducer of atrial fibrosis and arrhythmia in a mouse model of atrial fibrillation, and that myeloperoxidase levels are associated with atrial fibrillation in humans.

  • Volker Rudolph
  • , René P Andrié
  •  & Stephan Baldus